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Incidence of childhood leukaemia was studied among subjects of a vaccine trial in Finland comparing the polysaccharide–
diptheria toxoid conjugate and oligosaccharide–CRM197 conjugate Haemophilus inﬂuenzae type b conjugate vaccine
formulations. Eighty cases of childhood leukaemia were detected: 35 among children on the polysaccharide–diptheria toxoid
conjugate arm, and 45 among children on the oligosaccharide–CRM197 conjugate arm, which was not statistically signiﬁcant.
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A large case–control study conducted in the United States raised
the possibility that conjugate vaccine against Haemophilus inﬂuen-
zae type b (Hib) was inversely associated with the risk of childhood
leukaemia (Groves et al, 1999). Re-analysis of data from an earlier
clinical trial in Finland (Eskola et al, 1990) suggested a non-signif-
icant protective effect of early versus late administration of a Hib
conjugate vaccine (Auvinen et al, 2000). The present study aimed
to evaluate the effect of different formulations of a conjugate
Hib vaccine by exploiting a rare opportunity to compare different
formulations within the setting of an intervention trial was
provided by a nation-wide vaccination trial conducted in Finland
in the 1980s (Peltola et al, 1994). This approach minimises the
effects of bias and confounding due to known and unknown risk
factors.
MATERIALS AND METHODS
A nation-wide vaccine trial compared vaccination against Haemo-
philus inﬂuenzae type b (Hib) with a polysaccharide–diphtheria
toxoid conjugate (PRP-D) versus an oligosaccharide–CRM197
conjugate (HbOC) (Peltola et al, 1994). The PRP-D vaccine
consisted of heat-sized Hib capsular polysaccharide coupled to
diphtheria toxoid (Schneerson et al, 1980). All 125129 children
born in Finland between 1 September 1987 and 31 August 1989
were enrolled, with a participation rate of 93.8%. The children
were allocated to the trial arms based on the date of birth. All chil-
dren with an odd day of birth were assigned to the PRP-D arm,
while children with an even day of birth were assigned to the
HbOC arm; all children received three doses of Hib vaccine: the
ﬁrst at age 4 months, the second at age 6 months, and the third
(booster) dose between 14 and 18 months of age. All the children
also received standard vaccination regime including tuberculosis
(BCG), diphtheria–pertussis–tetanus (DPT), inactivated polio
(IPV) and measles–mumps–rubella (MMR) vaccine.
Information on the number of boys and girls born on odd and
even dates during the periods of interest were obtained from the
Finnish Population Registry (Table 1). Also, the number of chil-
dren alive in each group by year and sex was acquired. The
length of follow-up (through 1999) was 10–12 years among chil-
dren in the trial (born 1987–1989). All cases of childhood
leukaemia diagnosed in Finland were identiﬁed from the Finnish
Cancer Registry, which is a nation-wide, population-based cancer
registry (Teppo et al, 1994). Complete coverage of the cancer regis-
try was ensured by crosschecking the case lists at all hospitals
treating childhood leukemia and from mortality records. All child-
hood leukaemia cases were histologically conﬁrmed with bone
marrow aspirate.
Poisson regression analysis of leukaemia incidence rates was
conducted using the number of cases as the outcome variable, with
age, sex and cohort year of birth as covariates (Breslow and Day,
1987). For comparison of the PRP-D arm and the HbOC arm, a
binary variable based on odd or even date of birth was used.
Because of the shape of the age-incidence curve for childhood
leukaemia, rising to a peak in the early preschool years, then falling
before rising again, the square and cube of the age terms were also
entered into the model. Separate models were ﬁtted for acute
lymphoblastic leukaemia, all other leukemias combined, and all
leukaemias combined. The sex and cohort terms were not statisti-
cally signiﬁcant, and were removed from all three models. The
three age terms were statistically signiﬁcant for the models of acute
lymphoblastic leukaemia and total leukaemia, but were removed
from the model for other leukaemias because they were not statis-
tically signiﬁcant.
RESULTS
A total of 80 leukaemia cases were diagnosed from birth through
age 12 among subjects born during the trial period (1987–1989).
Of them, 35 were observed among children born on an odd date,
i.e., belonging to the PRP-D arm, while 45 were diagnosed among
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www.bjcancer.com1.14 (95% CI 0.63–2.08) for subjects in the HbOC group. Sixty-
nine of the cases were acute lymphoblastic leukaemias (ALL).
Among these cases, 30 were in the PRP-D and 39 in the HbOC
arm of the trial. The corresponding relative risk for the HbOC
arm was 1.01 (95% CI 0.53–1.93).
DISCUSSION
There was no suggestion of different risks of childhood leukaemia
among Finnish children who received the PRP-D or HbOC formu-
lations of Haemophilus inﬂuenzae type b conjugate vaccine. The
design of the trial with allocation of intervention based on date
of birth and prospective follow-up minimised the potential for bias
and confounding (Eskola et al, 1990; Peltola et al, 1994). Very high
participation rate reduced exposure misclassiﬁcation to a minimum
and complete ascertainment of cases was achieved by using the
data from the Finnish Cancer Registry (Teppo et al, 1994), based
on clinical, pathological and cause of death records. However, we
were not able to verify if the vaccination indeed took place for a
given individual, even though it was very likely given the participa-
tion rate of 93.8%. Lack of an effect in this analysis could reﬂect
similar effect of conjugate vaccines administered at an early age.
Alternatively, our ﬁndings can be taken to suggest that the earlier
results did not represent a causal relationship, i.e. lack of protective
effect of Haemophilus inﬂuenzae conjugate vaccination against
childhood leukaemia.
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